Optical coherence tomography biomarkers in patients with macular edema secondary to retinal vein occlusion treated with dexamethasone implant

Castro-Navarro, Verónica; Monferrer-Adsuara, Clara; Navarro-Palop, Catalina; Montero-Hernández, Javier; Cervera-Taulet, Enrique

doi:10.1186/s12886-022-02415-w

Table 3 Overview of the unadjusted mean changes from baseline to the last follow-up visit at month 6 between eyes with central retinal vein occlusion related macular edema (CVRO-ME) and those with macular edema secondary to branch retinal vein occlusion (BRVO-ME), and between treatment-naïve eyes and those previously treated

From: Optical coherence tomography biomarkers in patients with macular edema secondary to retinal vein occlusion treated with dexamethasone implant

Variables	Overall (n = 57)
Variables	Mean difference (95% CI) from baseline					P^b
BCVA	2.0 (−5.7 to 9.7)					0.6114
CRT, μm	− 240.7 (− 318.4 to − 162.9)					< 0.0001
CST, μm	1.7 (−17.8 to 21.3)					0.8594
NMCST500, μm	12.6 (−5.2 to 30.5)					0.1615
NMCST1500, μm	1.8 (−18.5 to 22.2)					0.8581
TMCST500, μm	7.4 (−14.4 to 29.3)					0.4992
TMCST1500, μm	12.6 (−8.0 to 33.2)					0.2257
Cyst volume, μm³	−195.8 (− 255.5 to − 136.1)					< 0.0001
SRF, μm	−114.3 (− 159.8 to −68.7)					< 0.0001
	CRVO (n = 15)		BRVO (n = 42)		Difference between treatment groups^c
	Mean difference (95% CI) from baseline	p^a	Mean difference (95% CI) from baseline	p^a	Median difference^d(95% CI)	P^b
BCVA	−9.5 (−25.5 to 6.5)	0.2248	6.1 (− 2.8 to 14.9)	0.1739	16.0 (0.0 to 35.0)	0.0798
CRT, μm	− 194.2 (− 340.7 to 47.7)	0.0130	−257.3 (−351.9 to −162.6)	< 0.0001	− 45.5 (− 227.0 to 127.0)	0.6311
CST, μm	15.0 (−30.2 to 60.2)	0.4883	−3.0 (− 25.2 to 19.2)	0.7859	−16.0 (−68.0 to 30.0)	0.4967
NMCST500, μm	25.9 (−10.6 to 62.5)	0.1502	7.9 (−13.3 to 29.0)	0.4556	−11.0 (−54.0 to 30.0)	0.6768
NMCST1500, μm	13.5 (−35.2 to 62.1)	0.5619	−2.3 (− 25.1 to 20.4)	0.8370	−6.5 (− 61.0 to 39.0)	0.7788
TMCST500, μm	7.7 (−56.2 to 71.7)	0.7990	7.3 (−14.1 to 28.7)	0.4943	−11.5 (− 55.0 to 31.0)	0.5259
TMCST1500, μm	19.1 (−38.2 to 76.4)	0.4856	10.3 (−10.8 to 31.3)	0.3302	−11.0 (−60.0 to 48.0)	0.5992
Cyst volume, μm³	− 140.1 (−267.5 to −12.7)	0.0335	− 216.2 (− 285.5 to − 146.8)	< 0.0001	−68.0 (− 207.0 to 85.0)	0.3323
SRF, μm	−58.3 (− 116.6 to 0.0)	0.0500	−139.9 (−200.5 to −79.4)	0.0001	−3.0 (− 60.0 to − 52.0)	0.6015
	Naïve (n = 31)		Previously treated (n = 26)		Difference between treatment groups^c
	Mean difference (95% CI) from baseline	p^a	Mean difference (95% CI) from baseline	p^a	Median difference (95% CI)^d	P^b
BCVA	11.0 (0.4 to 21.6)	0.0428	−8.8 (−19.2 to 1.6)	0.0928	−18.0 (−35.0 to −4.0)	0.0129
CRT, μm	− 269.8 (−399.4 to −140.3)	0.0002	−205.9 (−286.9 to − 124.9)	< 0.0001	41.5 (−120.0 to 197.0)	0.6251
CST	1.4 (−23.2 to 25.9)	0.9110	2.2 (−31.1 to 35.5)	0.8932	4.0 (−41.0 to 46.0)	0.8413
NMCST500	12.9 (−8.8 to 34.5)	0.2342	12.3 (−18.8 to 43.5)	0.4218	−3.0 (−40.0 to 33.0)	0.8039
NMCST1500	4.0 (−21.5 to 29.6)	0.7494	−0.8 (−35.4 to 33.8)	0.9620	−9.0 (−52.0 to 32.0)	0.6307
TMCST500	7.6 (−23.0 to 38.3)	0.6137	7.2 (−26.2 to 40.6)	0.6630	0.0 (− 36.0 to 43.0)	0.9872
TMCST1500	21.3 (−5.2 to 47.8)	0.1105	2.2 (−31.7 to 36.1)	0.8951	−4.0 (−47.0 to 39.0)	0.8538
Cyst volume, μm³	−218.8 (− 304.5 to − 133.2)	< 0.0001	− 169.2 (−256.9 to −81.5)	0.0005	70.5 (−80.0 to 181.0)	0.3653
SRF, μm	− 128.9 (−202.3 to − 55.5)	0.0015	−92.3 (− 133.9 to − 50.7)	0.0004	0.0 (−64.0 to 48.0)	0.8969

CRVO Central retinal vein occlusion, BRVO Branch retinal vein occlusion, CI Confidence interval, BCVA Best corrected visual acuity, CRT Central retinal thickness, CST Central subfoveal thickness, NRT Nasal retinal thickness, 500 ring of 500 μm, 1500 Ring of 1500 μm, TRT Temporal retinal thickness, SRF Subretinal fluid
^aTwo-way analysis of variance (ANOVA) test
^bMann-Whitney U test
^cFirst column versus (VS) the second one
^dHodges-Lehmann median difference (95% Confidence interval)

Back to article page

ISSN: 1471-2415

Contact us

General enquiries: journalsubmissions@springernature.com

BMC Ophthalmology

Contact us